Atara Biotherapeutics (ATRA) EBT (2013 - 2026)

Atara Biotherapeutics has reported EBT for 14 years, with the latest figure at -$4.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 110.91% year-over-year to -$4.1 million; the trailing twelve-month figure through Mar 2026 stood at -$42.2 million (down 169.01% YoY), and the FY2025 full-year result was -$18000.0, up 99.98% from the prior year.
• EBT for Q1 2026 stood at -$4.1 million, up from -$36.1 million in the prior quarter.
• The five-year high for EBT was $38.0 million in Q1 2025, with the low at -$88.1 million in Q1 2022.
• Historically, EBT has averaged -$35.0 million across 5 years, with a median of -$31.7 million in 2024.
• Annual changes were most pronounced in 2023 — EBT plunged 485.07% — and 2025, when it soared 219.8%.
• Atara Biotherapeutics' EBT stood at -$74.7 million in 2022, then climbed by 18.73% to -$60.7 million in 2023, then soared by 79.05% to -$12.7 million in 2024, then plunged by 184.32% to -$36.1 million in 2025, then jumped by 88.53% to -$4.1 million in 2026.
• The last three EBT figures came in at -$4.1 million (Q1 2026), -$36.1 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.